Parnassus Investments LLC decreased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 5.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 334,178 shares of the medical research company's stock after selling 18,365 shares during the quarter. Parnassus Investments LLC owned 0.18% of IQVIA worth $65,669,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Private Trust Co. NA increased its stake in IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock worth $115,000 after buying an additional 47 shares during the period. Pine Valley Investments Ltd Liability Co grew its stake in shares of IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock valued at $2,247,000 after acquiring an additional 50 shares in the last quarter. Howard Capital Management Inc. lifted its stake in shares of IQVIA by 4.9% in the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock worth $225,000 after acquiring an additional 54 shares in the last quarter. Huntington National Bank boosted its holdings in IQVIA by 7.4% in the third quarter. Huntington National Bank now owns 809 shares of the medical research company's stock valued at $192,000 after purchasing an additional 56 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in shares of IQVIA by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock valued at $1,068,000 after buying an additional 56 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on the stock. Robert W. Baird decreased their price objective on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, January 21st. Stifel Nicolaus reduced their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Royal Bank of Canada reissued an "outperform" rating and set a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Bank of America lowered their target price on IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a report on Friday, December 13th. Finally, William Blair restated an "outperform" rating on shares of IQVIA in a research report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $249.05.
Read Our Latest Analysis on IQV
IQVIA Stock Up 1.9 %
Shares of IQV traded up $3.55 during trading hours on Tuesday, hitting $188.45. 1,344,794 shares of the company were exchanged, compared to its average volume of 1,226,685. The firm's 50 day moving average is $196.34 and its 200-day moving average is $209.96. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52 week low of $179.28 and a 52 week high of $256.34. The company has a market cap of $33.23 billion, a PE ratio of 25.13, a PEG ratio of 1.99 and a beta of 1.50.
IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
